GIPR and type 2 diabetes mellitus: Combined GIPR/GLP1R agonism is superior to single GLP1R agonism with regard to glycemic control and lowering body weight in patients with type 2 diabetes.16, 17, 18 In fact, the GIPR and GLP1R dual agonist tirzepatide (Mounjaro®) has recently been approved by FDA to treat type 2 diabetes in humans.